There's a new bidding war brewing in the drug industry. Last week, Sanofi went public with a $9.3 billion bid for Medivation, a San Francisco-based biotech that already has one drug on the market to treat prostate cancer. Medivation turned …
A strong eurozone growth spurt failed to stir stock markets on Friday, as concerns about the US economy gnawed at investor confidence. A day after data showed the US economy has expanded at its slowest pace for two years, fresh …
Dow Jones Industrial Average News, 5/4/16 – In recent days, investors' sentiments have been rattled by weakness in China's manufacturing sector, a surprise cut in interest rates by the Reserve Bank of Australia, and a downgrade in …
Earnings matter as the primary motivation, but really it's the actual buying of a stock that is required to move its price higher as demand outstrips supply. And who does the kind of buying where demand outstrips supply? Institutions like …
Among large-cap pharma stocks, Bayer (BAYRY), a Zacks Rank #2 (Buy) stock, looks well-positioned with several new products -- Eylea, Stivarga and Xarelto -- in its portfolio. These products represent significant commercial potential. We …
So, when Pfizer announced that the company was not considering a split anymore, the market reacted by pushing the stock to edge lower. Now that the company has clearly announced its intentions, the issue can be put to rest and …